Evidence map›Paper›PMID 38805549›Full record

ArticlePLoS pathogens2024

Macrophage- and CD4+ T cell-derived SIV differ in glycosylation, infectivity and neutralization sensitivity.

Christina B Karsten, Falk F R Buettner, Samanta Cajic, Inga Nehlmeier, Berit Roshani, Antonina Klippert, Ulrike Sauermann, Nicole Stolte-Leeb, Udo Reichl, Rita Gerardy-Schahn and 3 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christina B KarstenInstitute for the Research on HIV and AIDS-associated Diseases, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0003-1934-6442
Falk F R BuettnerInstitute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany.
Samanta CajicglyXera GmbH, Magdeburg, Germany.
Inga NehlmeierInfection Biology Unit, German Primate Center-Leibniz Institute for Primate Research, Göttingen, Germany.
Berit RoshaniUnit of Infection Models, German Primate Center-Leibniz Institute for Primate Research, Göttingen, Germany.
Antonina KlippertNuvisan ICB GmbH, Berlin, Germany.
Ulrike SauermannUnit of Infection Models, German Primate Center-Leibniz Institute for Primate Research, Göttingen, Germany.
Nicole Stolte-LeebUnit of Infection Models, German Primate Center-Leibniz Institute for Primate Research, Göttingen, Germany.
Udo ReichlBioprocess Engineering Group, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany.
Rita Gerardy-SchahnInstitute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany.
Erdmann RappglyXera GmbH, Magdeburg, Germany.
Christiane Stahl-HennigUnit of Infection Models, German Primate Center-Leibniz Institute for Primate Research, Göttingen, Germany.
Stefan PöhlmannInfection Biology Unit, German Primate Center-Leibniz Institute for Primate Research, Göttingen, Germany.ORCID 0000-0001-6086-9136

Funding

Deutsche ForschungsgemeinschaftLeibniz FoundationOpen Access Publication Fund of the University of Duisburg-Essen
6 · The paper itself

Abstract

The human immunodeficiency virus (HIV) envelope protein (Env) mediates viral entry into host cells and is the primary target for the humoral immune response. Env is extensively glycosylated, and these glycans shield underlying epitopes from neutralizing antibodies. The glycosylation of Env is influenced by the type of host cell in which the virus is produced. Thus, HIV is distinctly glycosylated by CD4+ T cells, the major target cells, and macrophages. However, the specific differences in glycosylation between viruses produced in these cell types have not been explored at the molecular level. Moreover, it remains unclear whether the production of HIV in CD4+ T cells or macrophages affects the efficiency of viral spread and resistance to neutralization. To address these questions, we employed the simian immunodeficiency virus (SIV) model. Glycan analysis implied higher relative levels of oligomannose-type N-glycans in SIV from CD4+ T cells (T-SIV) compared to SIV from macrophages (M-SIV), and the complex-type N-glycans profiles seem to differ between the two viruses. Notably, M-SIV demonstrated greater infectivity than T-SIV, even when accounting for Env incorporation, suggesting that host cell-dependent factors influence infectivity. Further, M-SIV was more efficiently disseminated by HIV binding cellular lectins. We also evaluated the influence of cell type-dependent differences on SIV's vulnerability to carbohydrate binding agents (CBAs) and neutralizing antibodies. T-SIV demonstrated greater susceptibility to mannose-specific CBAs, possibly due to its elevated expression of oligomannose-type N-glycans. In contrast, M-SIV exhibited higher susceptibility to neutralizing sera in comparison to T-SIV. These findings underscore the importance of host cell-dependent attributes of SIV, such as glycosylation, in shaping both infectivity and the potential effectiveness of intervention strategies.

Indexed as

Antibodies, NeutralizingCD4-Positive T-LymphocytesMacrophagesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsGlycosylationHumansMacaca mulattaPolysaccharidesAntibodies, NeutralizingPolysaccharides

Identifiers

PMID38805549
PMCPMC11161069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.